Can a brain-computer interface truly restore human autonomy or is it just hype?
Neuralink is developing implantable brain-computer interfaces designed to bridge the gap between neural activity and digital control. While the company promises to restore function to those with paralysis and eventually enhance human cognition, its rapid development cycle and ambitious claims have sparked intense debate among scientists, ethicists, and regulators.
Founded in 2016 by Elon Musk and a team of eight experts, Neuralink aims to create a digital layer above the cortex. The technology utilizes a surgical robot to insert ultra-thin, flexible probes into the brain, which record electrical signals from neurons. These signals are processed by an integrated circuit and converted into binary code, theoretically allowing users to control external devices like computers or gaming systems through thought alone. The company's long-term vision includes treating neurological diseases and achieving symbiosis with artificial intelligence.
The path to human trials has been fraught with controversy. Early animal testing, involving at least 1,500 animals between 2018 and 2022, faced severe criticism from groups like the Physicians Committee for Responsible Medicine, which alleged that rushed timelines led to unnecessary suffering and death. Neuralink has consistently denied these claims, maintaining that its testing adheres to regulatory standards. Meanwhile, the FDA initially rejected the company's application for human trials in 2022, citing safety concerns regarding the device's lithium battery and the potential for wires to migrate within the brain, before granting approval in May 2023.
In 2024, the first human participant, Noland Arbaugh, demonstrated the device's potential by controlling a computer cursor. However, the trial also highlighted technical hurdles, including significant thread retraction caused by unexpected brain movement. Subsequent participants, such as the patient known as Alex, have seen improvements in implantation techniques designed to mitigate these issues. As of September 2025, Neuralink reported 12 trial participants with over 15,000 hours of cumulative usage. While some neuroscientists praise the engineering progress, others argue that the technology builds upon decades of existing research, leaving the ultimate impact of Neuralink’s approach a subject of ongoing scientific and ethical scrutiny.
Source: Neuralink
